The ITI Techmedia Biosensing R&D Programme aims to create a modular prototype technology platform that will enable rapid multi-parameter measurement of protein, nucleic acid and small molecules from whole blood.

Working in an emerging technology area, known as ‘theranostics’, the proposed solution combines diagnosis and therapeutic guidance to tailor treatments for individual patients. The technology aims to reduce the cost and complexity of disease diagnosis and treatment in the clinical environment, and offers the ability to manage both disease progression and drug therapy effects. Theranostic solutions are already in use in the treatment of various cancers where therapy can be determined by performing specific tests. The development of this technology platform could see similar solutions becoming mainstream for a range of diseases, including infections and cancers.

The fifth R&D Programme in the ITI Techmedia portfolio, the Biosensing Programme Platform has now been completed, with a total investment of over £11 million from ITI Techmedia. Various exciting licensing opportunites exist to exploit the technology generated by the Programme. To discuss becoming a Commercial Partner and to explore the commercial opportunities in more detail, please contact Gillian Brown, ITI Techmedia Director of Commercialisation, +44(0)141 240 1187or email gillian.brown@ititechmedia.com